Tag Archives: Raju Prasad

William Blair Sticks to Their Hold Rating for Bluebird Bio (BLUE)

William Blair analyst Raju Prasad maintained a Hold rating on Bluebird Bio (BLUE – Research Report) today. The company’s shares closed last Friday at $56.75. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 15.6% and

William Blair Maintains Their Buy Rating on Assembly Biosciences (ASMB)

William Blair analyst Raju Prasad maintained a Buy rating on Assembly Biosciences (ASMB – Research Report) today. The company’s shares closed last Thursday at $20.85. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 15.4% and

Poseida Therapeutics (PSTX) Has a New Rating from William Blair

In a report released today, Raju Prasad from William Blair initiated coverage with a Buy rating on Poseida Therapeutics (PSTX – Research Report). The company’s shares closed last Thursday at $9.11, close to its 52-week low of $8.38. According to

Poseida Therapeutics (PSTX) Received its Third Buy in a Row

After Merrill Lynch and Piper Sandler gave Poseida Therapeutics (NASDAQ: PSTX) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Raju Prasad initiated coverage with a Buy rating on Poseida Therapeutics today. The

William Blair Sticks to Its Buy Rating for Logicbio Therapeutics (LOGC)

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Logicbio Therapeutics (LOGC – Research Report). The company’s shares closed last Friday at $7.86. According to TipRanks.com, Prasad is a 5-star analyst with an average

William Blair Sticks to Their Buy Rating for Krystal Biotech (KRYS)

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech (KRYS – Research Report). The company’s shares closed last Tuesday at $42.82. According to TipRanks.com, Prasad is a 5-star analyst with an average